Association of Systemic Inflammatory Response Index and Pan-Immune-Inflammation-Value with Long-Term Adverse Cardiovascular Events in ST-Segment Elevation Myocardial Infarction Patients After Primary Percutaneous Coronary Intervention
Yehong Liu,Jie Liu,Longqun Liu,Shaoqing Cao,Tianhui Jin,Liang Chen,Gangyong Wu,Gangjun Zong
DOI: https://doi.org/10.2147/jir.s421491
IF: 4.5
2023-08-15
Journal of Inflammation Research
Abstract:Yehong Liu, 1, &ast Jie Liu, 1, &ast Longqun Liu, 2, &ast Shaoqing Cao, 1, 3 Tianhui Jin, 1 Liang Chen, 1, 3 Gangyong Wu, 1, 3 Gangjun Zong 1, 3 1 Department of Cardiology, The 904th Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu, People's Republic of China; 2 Department of Respirology, The 904th Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu, People's Republic of China; 3 Department of Cardiology, Wuxi Clinical College of Anhui Medical University, Wuxi, Jiangsu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Gangyong Wu; Gangjun Zong, Email ; Aim: Reducing the high morbidity and mortality of ST-segment elevation myocardial infarction (STEMI) and improving patient prognosis remains a major global challenge. This study aimed to explore whether dynamic fluctuations in biomarkers are valuable predictors of prognosis in patients with STEMI. Methods: This study included 216 patients with STEMI. Blood routine tests were performed on admission, 12 h after percutaneous coronary intervention (PCI), and at discharge. Systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and pan-immune-inflammation-value (PIV) serum immune-inflammatory markers were calculated. The Cox proportional hazard model was used to assess the factors independently associated with the prognosis of STEMI. The optimal cutoff values for the inflammatory markers were calculated. Results: Eighty-five (39.35%) of the 216 patients had major adverse cardiovascular events (MACEs) during the 1-year follow-up. Most were male (81.18%) with a median age of 64 years (interquartile, 55– 69.5). Killip class ≥ II on admission (hazard ratio [HR], 1.859; 95% CI, 1.169– 2.957; P = 0.009), total stent length (HR, 1.016; 95% CI, 1.003– 1.029; P = 0.019), values of SIRI at 12 h after PCI (HR, 1.079; 95% CI, 1.050– 1.108; P < 0.001), and the Gensini score (HR, 1.014; 95% CI, 1.007– 1.022; P < 0.001) were independently associated with an increased risk of MACEs. Compared with SII, SIRI and PIV calculated at various time points and dynamically fluctuating changes, SIRI (cutoff value, 4.15; 95% CI, 0.701– 0.819; P < 0.001) and PIV (cutoff value, 622.71; 95% CI, 0.674– 0.796; P < 0.001) at 12 h after PCI showed the best efficacy for the prognosis of STEMI. Conclusion: Our study provides relevant evidence to the notion that SIRI or PIV at 12 h after PCI may be more accurate and economical predictors of long-term adverse prognosis in patients with STEMI. Keywords: systemic inflammatory response index, pan-immune-inflammation-value, ST-segment elevation myocardial infarction, major adverse cardiovascular events, prognosis, percutaneous coronary intervention Cardiovascular diseases are the leading cause of death worldwide, with ischemic heart disease being the most common type. 1 ST-segment elevation myocardial infarction (STEMI) is the most serious manifestation of ischemic heart disease. Based on the national registries of the European Society of Cardiology) countries, the incidence rate of STEMI in other European countries ranged from 43 to 144 per 100000 per year in 2015, and in-hospital mortality rates for patients with STEMI varied between 4% and 12%, while the 1-year mortality among patients with STEMI in angiography registries was approximately 10%. 2 Reducing the high morbidity and mortality of STEMI and improving patient prognosis remains a major global challenge. 2,3 The age of onset of STEMI has progressively decreased and it is crucial to reduce the economic burden of the disease and improve the quality of life and prognosis of patients through early and accurate diagnosis, rapid and effective treatment, and accurate prediction of prognosis. 4 Accurate identification of the clinical features of patients with STEMI with adverse cardiovascular events after hospital discharge may contribute to the screening of high-risk patients, development of individualized treatments, optimization of post-discharge management, and improvement in clinical prognosis. 5 Previous studies have shown that the immunoinflammatory response plays an important role in the pathogenesis of myocardial infarction (MI) and is also closely related to clinical prognosis. 6–9 Serum inflammatory markers such as lymphocytes, neutrophils, monocytes, and platelets, infiltrate atherosclerotic lesions and initiate cytokine cascade reactions leading to the onset and progression of coronary lesions. 10,11 Blood tests, including l -Abstract Truncated-
immunology